Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.

Reuters12-12

Dec 12 (Reuters) - Genmab A/S ::
*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD
*EXPECTS TO LAUNCH PETOSEMTAMAB IN 2027
*INTENDS TO BROADEN AND ACCELERATE PETOSEMTAMAB'S DEVELOPMENT WITH POTENTIAL EXPANSION INTO OTHER LINES OF THERAPY
*BELIEVES THAT PETOSEMTAMAB WILL BE ACCRETIVE TO EBITDA WITH AT LEAST ONE-BILLION-DOLLAR ANNUAL SALES POTENTIAL BY 2029
*94.2% OF MERUS SHARES TENDERED IN GENMAB'S OFFER

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 12-DEC-202506:35:28.927 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590057359?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 15:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590057359","market":"us","top_or_hot":-1,"title":"Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.","media":"Reuters","content":"<html><body>Dec 12 (Reuters) - <a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> <gmab.co>::<br/>*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD<br/>*EXPECTS TO LAUNCH PETOSEMTAMAB IN 2027<br/>*INTENDS TO BROADEN AND ACCELERATE PETOSEMTAMAB'S DEVELOPMENT WITH POTENTIAL EXPANSION INTO OTHER LINES OF THERAPY<br/>*BELIEVES THAT PETOSEMTAMAB WILL BE ACCRETIVE TO EBITDA WITH AT LEAST ONE-BILLION-DOLLAR ANNUAL SALES POTENTIAL BY 2029<br/>*94.2% OF MERUS SHARES TENDERED IN GENMAB'S OFFER<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 12-DEC-202506:35:28.927 GMT</gmab.co></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 15:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Dec 12 (Reuters) - <a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> <gmab.co>::<br/>*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD<br/>*EXPECTS TO LAUNCH PETOSEMTAMAB IN 2027<br/>*INTENDS TO BROADEN AND ACCELERATE PETOSEMTAMAB'S DEVELOPMENT WITH POTENTIAL EXPANSION INTO OTHER LINES OF THERAPY<br/>*BELIEVES THAT PETOSEMTAMAB WILL BE ACCRETIVE TO EBITDA WITH AT LEAST ONE-BILLION-DOLLAR ANNUAL SALES POTENTIAL BY 2029<br/>*94.2% OF MERUS SHARES TENDERED IN GENMAB'S OFFER<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 12-DEC-202506:35:28.927 GMT</gmab.co></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nRSD2zqMD7:1","article_id":"2590057359","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590057359","pubTimestamp":1765522931,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dec 12 (Reuters) - Genmab A/S ::*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD*EXPECTS TO LAUNCH PETOSEMTAMAB I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","MRUS":"Merus B.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Genmab：完成对Merus N.V.已发行普通股的要约收购。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRUS":0.9},"content_text":"Dec 12 (Reuters) - Genmab A/S ::*GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD*EXPECTS TO LAUNCH PETOSEMTAMAB IN 2027*INTENDS TO BROADEN AND ACCELERATE PETOSEMTAMAB'S DEVELOPMENT WITH POTENTIAL EXPANSION INTO OTHER LINES OF THERAPY*BELIEVES THAT PETOSEMTAMAB WILL BE ACCRETIVE TO EBITDA WITH AT LEAST ONE-BILLION-DOLLAR ANNUAL SALES POTENTIAL BY 2029*94.2% OF MERUS SHARES TENDERED IN GENMAB'S OFFER  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-DEC-202506:35:28.927 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590057359","isCrawlerRequest":true}